Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD.
Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness.
- Aids readers in understanding major depressive disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations
- Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments, to antidepressants and novel therapeutics
- Synthesizes discussions on the cellular and molecular mechanisms underlying symptoms with the clinical aspects of depression
Advanced students and researchers in neuroscience, psychology, medicine, health sciences, and pharmacology
1. The classification of depression: embracing phenotypic heterogeneity in the era of the RDoC
2. The role of environmental and psychosocial factors in depression
3. Cognitive dysfunction in depression: evidence, pathophysiology, and treatment
4. Anhedonia in depression: assessment, mechanisms, and therapeutics
5. Gene-environment interactions and epigenetics mechanisms in depression
6. The neurotrophic hypothesis of depression revisited: new insights and therapeutic implications
7. The monoamine hypothesis of depression revisited: could it mechanistically novel antidepressant strategies?
8. Neuro-immune interactions in depression: mechanisms and translational implications
9. The hypothalamic-pituitary-adrenal axis in depression: pathophysiological role and translational implications
10. Advances in the neurobiology of late-life depression
11. Advances in the neurobiology of pediatric depression
12. The long-lasting neurobiological scars of early life stress: implications to the neurobiology of depression
13. Animal models of depression: recent advances and limitations
14. More than a gut feeling: emerging roles of the microbiome in the pathophysiology and treatment of depression
15. Optogenetics: emerging insights to the neurobiology of depression
16. Mitochondrial dysfunction and oxidative stress: relevance to the pathophysiology and treatment of depression
17. Obesity and depression: shared pathophysiology and translational implications
18. Depression and cardiovascular risk: epidemiology, mechanisms and implications
19. Is depression associated with accelerated aging? Mechanisms and implications
20. Relationships between complicated grief and depression: relevance, pathophysiological mechanisms and implications
21. Neuroimaging abnormalities in depression: research synthesis and translational perspectives
22. Could depression be preventable? Evidence and perspectives
23. Treating depression in the era of precision medicine: challenges and perspectives
24. Diet and depression: from epidemiology to novel therapeutics
25. Exercise as a treatment of depression: evidence and neurobiological mechanisms
26. Antidepressants and suicidality: controversies and possible mechanisms
27. Novel neuromodulatory approaches for depression: neurobiological mechanisms
28. Electroconvulsive therapy for depression: neurobiological mechanisms
29. Deep brain stimulation: mechanisms underpinning antidepressant effects
30. Novel therapeutic targets for major depressive disorder
31. The search for fast-acting antidepressants: research synthesis and perspectives
- No. of pages:
- © Academic Press 2019
- 1st March 2019
- Academic Press
- Paperback ISBN:
João Quevedo is Professor of Psychiatry at the McGovern Medical School, The University of Texas Health Science Center at Houston, where he is Vice-Chair for Faculty Development and Outreach, Director of the Translational Psychiatry Program, and Director of the Treatment-Resistant Mood Disorder Program. Before moving to Houston he was Dean at the University of Southern Santa Catarina Medical School, Criciúma, SC, Brazil, where he is still Adjunct Professor of Psychiatry. He is also an 1A research fellow (the highest level) of the National Council for Scientific and Technological Development (CNPq), Brazil; an affiliate member of the Brazilian Academy of Sciences (an award given to the most notable researchers in Brazil under the age of 40), associate editor of the Revista Brasileira de Psiquiatria, vice president of the Santa Catarina State Association of Psychiatry, and Director of the Continuous Medical Education Program in Psychiatry (PROPSIQ) of the Brazilian Association of Psychiatry. Dr. Quevedo’s research interest is the neurobiology of psychiatric disorders, particularly mood disorders, and he is a specialist in animal models of depression and bipolar disorder. He is author of nearly 500 publications and 6 scientific books.
Professor, Vice-Chair for Faculty Development and Outreach, Director of the Translational Psychiatry Program, Director of the Treatment-Resistant Mood Disorders Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Sciences Center at Houston (UTHealth), Houston, Texas, United States
André F Carvalho is associate professor at the Department of Psychiatry at the University of Toronto and a clinician scientist at the Centre for Addiction and Mental Health (CAMH). He was elected member of the board of councilors of the International Society of Bipolar Disorders (2016-2017) and the vice-chair of the section of private practice psychiatry of the World Psychiatric Association (2015-2017). He sits on the editorial board of several international peer-reviewed journals, including Psychotherapy and Psychosomatics, and has served as a peer reviewer for several leading journals and funding agencies. He is an expert in mood disorders, psychiatric epidemiology, and evidence-based mental health. Dr. Carvalho is a sought after speaker in several national and international meetings, and is the author of over 300 publications.
Associate Professor, Department of Psychiatry, University of Toronto Clinician Scientist, Centre for Addiction and Mental Health (CAMH) Toronto, ON, Canada
Carlos A. Zarate, Jr., is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the National Institute of Mental Health, and Clinical Professor of Psychiatry and Behavioral Sciences, at The George Washington University. Dr. Zarate completed a Fellowship in Clinical Psychopharmacology at McLean Hospital from 1992-1993, after which he remained as a staff member until 1998. At the McLean Hospital Consolidated Department of Psychiatry, Harvard Medical School, Dr. Zarate was the Director of the Bipolar and Psychotic Disorders Outpatient Services, Chair of the Pharmacy and Therapeutic Committee, and Director of the New and Experimental Clinic. From 1998 to 2000, Dr. Zarate was the Chief of the Bipolar and Psychotic Disorders Program, Associate Professor of Psychiatry, and Chair of the Grand Rounds Committee at the University of Massachusetts Medical School. In January 2001, he joined the Mood and Anxiety Disorders Program at the NIMH as Chief of the Mood Disorders Research Unit. In 2009, Dr. Zarate formed the Experimental Therapeutics and Pathophysiology Branch at the NIMH. He is the recipient of numerous awards and the author of more than 250 publications.
Chief Experimental Therapeutics & Pathophysiology Branch & Section Neurobiology and Treatment of Mood Disorders, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, United States